Fixed-dose combination of cefepime plus amikacin (potentox) inhibits pneumonia infection

Experimental Lung Research

Volumn 35, Issue 7, 2009, Pages 621-629

  Dwivedi, V K ^a   Soni, A ^a   Chaudhary, M ^a   Singh, C P ^a   Shrivastava, S M ^a  

^a Venus Medicine Research Centre   (India)

Author keywords

antioxidant enzymes; Klebsiella pneumoniae; malonaldialdehyde; oxidative stress; pneumonia; potentox

Indexed keywords

AMIKACIN PLUS CEFEPIME; ANTIBIOTIC AGENT; CATALASE; MALONALDEHYDE; OXIDIZING AGENT; POTENTOX; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; AMIKACIN; ANTIINFECTIVE AGENT; ANTIOXIDANT; CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEVER; KLEBSIELLA PNEUMONIAE; LIPID PEROXIDATION; LUNG PARENCHYMA; MALE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT; TISSUE LEVEL; WEIGHT REDUCTION; ANIMAL; BACTERIAL PNEUMONIA; DRUG COMBINATION; DRUG EFFECT; KLEBSIELLA INFECTION; METABOLISM; OXIDATIVE STRESS; WISTAR RAT;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; CATALASE; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PNEUMONIA, BACTERIAL; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 75549089604     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.1080/01902140902833269     Document Type: Article

References (26)

1. Jacoby GA, Medeiros AA: More extended-spectrum β-lactamase. Antimicrob Agents Chemother. 1991;35:1697-1704.
2. Barbahiya RH, Knupp CA, Pferrer M, Pittman KA: Lack of pharmacokinetic interaction between cefepime and amikacin in humans. Antimicrob Agents Chemother. 1992;36:1382-1386.
3. Hoffken G, Niederman MS: Nosocomial pneumonia: The importance of de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest. 2002;122:2183-2196.
4. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH: The occurrence of ventilator-associated pneumonia in a community hospital: risk factor and clinical out comes. Chest. 2001;120:555-561.
5. Tumah H: Fourth generation cephalosporins: in vitro activity againest nosocomial gram negative bacilli compared with beta-lactam antibiotics and ciprofloxacin. Chemotherapy. 2005;51:80-85.
6. Cantin A, Woods DE: Protection by antibiotics against myeloperoxidase-dependant cytotoxicity to lung epithelial cells in vitro. J Clin Invest. 1993;91:38-45.
7. Phelps DJ, Carlton DD, Farrell CA, Kessler RE: Affinity of cephalosporins for beta-lactamases as a factor in bacterial efficacy. Antimicrob Agents Chemother. 1986;29:845-848.
8. Bodmann KF: Current guideline for the treatment of severe pneumonia and sepsis. Chemotherapy. 2005;51:227-33.
9. Edson RS, Terrell CL: The aminoglycosides. Mayo Clin Proc. 1999;74:519-528.
10. Cheer SM, Waugh J, Noble S: Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63:2501-2520.
11. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF: In vitro activities of various beta-lactam antimicrobial against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother. 1995;39:1187-1190.
12. Held TK, Mielke MEA, Chedid M, Unger M, Trautmann M, Huhn D, et al: Granulocyte colonystimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria. Blood. 1998;91:2525-35.
13. Misra HP, Fridovich I: The role of superoxide anion in the auto-oxidation of epinephrine and as sample assay for superoxide dismutase. J Biol Chem. 1972;247:3170-3175.
14. Luck: Catalase. In: Bergmeyer HU, ed. Method in Enzymatic Analysis. San Diego: Academic Press; 1965:885-894.
15. Ohkawa H, Ohishi N, Yagi K: Assay of lipid per-oxidation in animal tissue by thiobarbutric acid reaction. Anal Biochem. 1979;95:351-358.
16. Philip OR, Judy MHD, Philip M, Young KR, Sadis M: The role of nitric oxide in lung innate immunity: modulation by surfactant protein-A. Mole Cell Biochem. 2002;234-235:39-48.
17. Sibille Y, Reynold HY: Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990;141:471-501.
18. Nathan CF: Secreatory products of macrophages. J Clin Invest. 1987;79:319-326.
19. Davis JM, Rosenfeld W: Chronic lung disease. In: Avery G, Fletcher M, MacDonald M., eds. Neonatology. Philadelphia: Lippincott, Williams & Wilkins; 1999:509-532.
20. Schraufsttter IU, Cochrane CG: Oxidants: types, sources, and mechanisms of injury. In: Crystal RG, West JB, eds. The Lung. New York: Raven Press; 1991:1803-1810.
21. Heffner JE, Repine JE: Antioxidants and the lung. In: Crystal RG, West JB, eds. The Lung. NewYork: Raven Press; 1991:1811-1820.
22. Schoonen WG, Wanamarta AH, Van der Klei-Van Moorsel JM, Jakobs C, Joenje H: Respiratory failure and stimulation of glycolysis in Chinese hamster ovary cells exposed to normobaric hyperoxia. J Biol Chem. 1990;265:1118-1124.
23. Sullivan SJ, Roberts RJ, Spitz DR: Replacement of media in cell culture alters oxygen toxicity: possible role of lipid aldehydes and glutathione transferase in oxygen toxicity. J Cell Physiol. 1991;147:427-433.
24. Chaudhary M, Soni A, Dwivedi VK: Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice. Cur Clin Phamacol. 2008;3:211-214.
25. Chaudhary M, Soni A, Dwivedi VK, Sehgal R: Antioxidant property of new cephalosporinaminoglycodside fixed dose combination. Curr Drug Ther. In press.
26. Chaudhary M, Shrivastava SM: Minimum inhibitory concentration of ceftriaxone and vancomycin in penicillin resistant Staphylococcus aureus, Entrococcus faecalis and Streptococcus pneumoniae. J Natcon 2006;18:177-180.